Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma - Case Series and Review

Klinische Monatsblatter fur Augenheilkunde

Volumn 233, Issue 4, 2016, Pages 540-544

  Fierz, F C ^a,b   Meier, F ^a   Chaloupka, K ^a   Böni, Christian ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

BRAF inhibition; CTLA 4 inhibition; immune related adverse events; intraocular inflammation; ipilimumab; ocular side effects; uveitis; vemurafenib; Vogt Koyanagi Harada

Indexed keywords

INDOCYANINE GREEN; IPILIMUMAB; NIVOLUMAB; PREDNISOLONE ACETATE; PREDNISONE; SCOPOLAMINE; STEROID; VEMURAFENIB; ANTINEOPLASTIC AGENT;

ADULT; ANTERIOR EYE CHAMBER; ARTICLE; BLURRED VISION; CASE REPORT; CHOROID DISEASE; CHOROIDITIS; CUTANEOUS MELANOMA; DISC SWELLING; DRUG WITHDRAWAL; EYE DISCOMFORT; EYE INFLAMMATION; EYE SYNECHIA; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; INTERMEDIATE UVEITIS; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; MALE; MEDICAL ONCOLOGIST; METASTATIC MELANOMA; MIDDLE AGED; OUTCOME ASSESSMENT; RETINA VASCULITIS; SLIT LAMP; STEROID THERAPY; SWELLING; SYSTEMIC THERAPY; TREATMENT DURATION; UVEITIS; VISUAL ACUITY; CHEMICALLY INDUCED; DIFFERENTIAL DIAGNOSIS; MELANOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME; UVEITIS;

EID: 84967153386     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0042-102668     Document Type: Article

References (30)

1. Chapman P. B., Hauschild A., Robert C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med: 2011; 364 2507 2516
2. Hodi F. S., O'Day S. J., McDermott D. F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med: 2010; 363 711 723
3. Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo): 2013; 2013 857519
4. Papavasileiou E., Prasad S., Freitag S. K. et al. Ipilimumab-induced ocular and orbital inflammation-A case series and review of the literature. Ocul Immunol Inflamm: 2015; Aug 24 [Epub ahead of print]: 1-7
5. Dudley M. E., Wunderlich J. R., Yang J. C. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol: 2005; 23 2346 2357
6. Yeh S., Karne N. K., Kerkar S. P. et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology: 2009; 116 981 989 e1
7. Sober A. J., Haynes H. A. Uveitis, poliosis, hypomelanosis, and alopecia in a patient with malignant melanoma. Arch Dermatol: 1978; 114 439 441
8. Aisenbrey S., Luke C., Ayertey H. D. et al. Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up. Graefes Arch Clin Exp Ophthalmol: 2003; 241 996 999
9. Ueda H., Howson J. M., Esposito L. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature: 2003; 423 506 511
10. Du L., Yang P., Hou S. et al. Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome. Clin Immunol: 2008; 127 43 48
11. Sugita S., Takase H., Taguchi C. et al. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci: 2006; 47 2547 2554
12. Attia P., Phan G. Q., Maker A. V. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol: 2005; 23 6043 6053
13. Downey S. G., Klapper J. A., Smith F. O. et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res: 2007; 13 6681 6688
14. Weber J. S., O'Day S., Urba W. et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol: 2008; 26 5950 5956
15. Robinson M. R., Chan C. C., Yang J. C. et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother: 2004; 27 478 479
16. Yeh O. L., Francis C. E. Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol: 2015; 35 144 147
17. Borodic G., Hinkle D. M., Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg: 2011; 27 e87 e88
18. Crosson J. N., Laird P. W., Debiec M. et al. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother: 2015; 38 80 84
19. Wong R. K., Lee J. K., Huang J. J. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep: 2012; 6 423 426
20. Weber J. S., Dummer R., de Pril V. et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer: 2013; 119 1675 1682
21. Choe C. H., McArthur G. A., Caro I. et al. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol: 2014; 158 831 837 e2
22. Lemech C., Arkenau H. T. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol: 2012; 6 53 66
23. Guedj M., Queant A., Funck-Brentano E. et al. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib. JAMA Ophthalmol: 2014; 132 1421 1425
24. Wolf S. E., Meenken C., Moll A. C. et al. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer: 2013; 13 561
25. Joshi L., Karydis A., Gemenetzi M. et al. Uveitis as a result of MAP kinase pathway inhibition. Case Rep Ophthalmol: 2013; 4 279 282
26. Draganova D., Kerger J., Caspers L. et al. Severe bilateral panuveitis during melanoma treatment by dabrafenib and trametinib. J Ophthalmic Inflamm Infect: 2015; 5 17
27. Horvat T. Z., Adel N. G., Dang T. O. et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol: 2015; 33 3193 3198
28. Miserocchi E., Cimminiello C., Mazzola M. et al. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol: 2015; 50 e2 e4
29. Nallapaneni N. N., Mourya R., Bhatt V. R. et al. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Canc Netw: 2014; 12 1077 1081
30. Liao B., Shroff S., Kamiya-Matsuoka C. et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol: 2014; 16 589 593